Evolent Clinical Guideline 3081 for Mekinist™ (trametinib)

Guideline Number:	Applicable Codes	
Evolent_CG_3081		
"Evolent" refers to Evolent Health LLC and Evolent Specialty Services, Inc. *© 2013 - 2026 Evolent. All rights Reserved.*		
Original Date:	**Last Revised Date:**	**Implementation Date:**
September 2013	May 2026	May 2026

TABLE OF CONTENTS

STATEMENT **2**
- PURPOSE 2

INDICATIONS **2**
- LOW GRADE GLIOMA 2
- MALIGNANT MELANOMA 2
- NON-SMALL CELL LUNG CANCER (NSCLC) 2
- SOLID TUMORS WITH BRAF V600E MUTATION (EXCLUDING COLORECTAL CANCER) 3
- THYROID CARCINOMA 3

CONTRAINDICATIONS/WARNINGS **3**

EXCLUSION CRITERIA **3**

CODING AND STANDARDS **4**
- CODES 4
- APPLICABLE LINES OF BUSINESS 4

POLICY HISTORY **5**

LEGAL AND COMPLIANCE **5**
- GUIDELINE APPROVAL 5
  - *Committee* *5*
- DISCLAIMER 5

REFERENCES **6**

STATEMENT

Purpose

To define and describe the accepted indications for Mekinist (trametinib) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

Evolent is responsible for processing all medication requests from network ordering providers. Medications not authorized by Evolent may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

INDICATIONS

Continuation requests for a not-approvable medication shall be exempt from this Evolent policy provided

- The member has not experienced disease progression on the requested medication AND
- The requested medication was used within the last year without a lapse of more than 30 days of having an active authorization AND
- Additional medication(s) are not being added to the continuation request.

Low Grade Glioma

- Mekinist (trametinib) may be used in combination with Tafinlar (dabrafenib) in members 1 year of age and older with low grade glioma with a BRAF V600E mutation.

Malignant Melanoma

- Mekinist (trametinib) may be used as adjuvant treatment, following complete resection, in combination with Tafinlar (dabrafenib) for melanoma with BRAF V600E or V600K mutations OR
- Mekinist (trametinib) may be used in combination with Tafinlar (dabrafenib) in members with unresectable or metastatic BRAF V600E or V600K mutation positive melanoma.

Non-Small Cell Lung Cancer (NSCLC)

- The member has recurrent, advanced, or metastatic BRAF V600E mutation-positive NSCLC and Mekinist (trametinib) is being used in combination with Tafinlar (dabrafenib) as any of the following:
    - First line therapy OR

- Subsequent therapy if anti-BRAF targeted therapy was not previously used.

Solid Tumors with BRAF V600E mutation (excluding colorectal cancer)

- Mekinist (trametinib) may be used in combination with Tafinlar (dabrafenib) in adult or pediatric members greater than or equal to 1 year of age with unresectable or metastatic solid tumors with BRAF V600E mutation, as subsequent therapy.

Thyroid Carcinoma

- Mekinist (trametinib) is being used in combination with Tafinlar (dabrafenib) for radioactive iodine-refractory (if radioactive iodine therapy is appropriate) in members with locally advanced or metastatic BRAF V600E mutation-positive anaplastic, papillary, follicular, or Hürthle Cell thyroid cancer.

CONTRAINDICATIONS/WARNINGS

- None

EXCLUSION CRITERIA

- The member has BRAF wild-type tumors.
- Disease progression while taking any MEK inhibitor + BRAF inhibitor combination.
- Dosing exceeds single dose limit of Mekinist (trametinib) 2 mg.
- Treatment exceeds the maximum limit of 30 (2 mg) or 90 (0.5 mg) tablets/month, or 14 (0.05 mg/1 mL) bottles of oral solution/month.
- Treatment exceeds the maximum 12 months duration limit when used as adjuvant melanoma treatment following complete resection of the primary lesion and completion of a regional lymph node dissection.
- Investigational use of Mekinist (trametinib) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
  - Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
  - Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
  - Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definitions of Clinically Meaningful outcomes

are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.

- Whether the experimental design, considering the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
- That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
- That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
- That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

CODING AND STANDARDS

Codes

- J8999 - trametinib

Applicable Lines of Business

☐	CHIP (Children's Health Insurance Program)
☒	Commercial
☒	Exchange/Marketplace
☒	Medicaid
☐	Medicare Advantage

POLICY HISTORY

Date	Summary
May 2026	• Added oral solution formulation details to exclusion criteria • Updated references
May 2025	• Converted to new Evolent guideline template • This guideline replaces UM ONC_1249 Mekinist (trametinib) • Updated solid tumor indication section to include use in pediatric members ≥ 1 year of age • Updated maximum dosage form quantities in exclusion criteria • Updated exclusion criteria • Updated references
May 2024	• Added new reference • Updated NCH verbiage to Evolent

LEGAL AND COMPLIANCE

Guideline Approval

Committee

Reviewed / Approved by Evolent Specialty Services Clinical Guideline Review Committee

Disclaimer

Evolent Clinical Guidelines do not constitute medical advice. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Evolent uses Clinical Guidelines in accordance with its contractual obligations to provide utilization management. Coverage for services varies for individual members according to the terms of their health care coverage or government program. Individual members' health care coverage may not utilize some Evolent Clinical Guidelines. Evolent clinical guidelines contain guidance that requires prior authorization and service limitations. A list of procedure codes, services or drugs may not be all inclusive and does not imply that a service or drug is a covered or non-covered service or drug. Evolent reserves the right to review and update this Clinical Guideline in its sole discretion. Notice of any changes shall be provided as required by applicable provider agreements and laws or regulations. Members should contact their Plan customer service representative for specific coverage information.

REFERENCES

1. Subbiah V, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. *Ann Oncol*. 2022 Apr;33(4):406-415. doi: 10.1016/j.annonc.2021.12.014.
2. Planchard D, et al. Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. *J Thorac Oncol*. 2022 Jan;17(1):103-115. doi: 10.1016/j.jtho.2021.08.011.
3. Robert C, et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. *N Engl J Med*. 2019 Aug 15;381(7):626-636. doi: 10.1056/NEJMoa1904059.
4. Consoli F, et al. Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma. *Clin Transl Oncol*. 2020 Jun;22(6):900-907. doi: 10.1007/s12094-019-02207-7.
5. Mekinist prescribing information. Novartis Pharmaceuticals Corporation. East Hanover, NJ 2026.
6. Clinical Pharmacology Elsevier Gold Standard 2026.
7. Micromedex® Healthcare Series: Micromedex Drugdex Ann Arbor, Michigan 2026.
8. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2026.
9. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD 2026.
10. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol*. 2014 Apr 20;32(12):1277-80.
11. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: **https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf**.
12. Current and Resolved Drug Shortages and Discontinuations Reported to the FDA: **http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm**.